Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic, Inc. (HOLX) reported Q4 FY2022 revenue of $953 million, a 27.6% decline from the previous year, yet outperforming guidance of $840-870 million. GAAP diluted EPS was $0.47, down 63.3%, while non-GAAP diluted EPS was $0.82, down 49.1%. Diagnostics revenue fell 37.8%, chiefly due to decreased COVID-19 assay sales. Despite the challenges, organic growth in Molecular Diagnostics (up 17.2%) and a 9.3% rise in Surgical revenue were notable. For FY2023, guidance anticipates revenue between $3.7 billion and $3.9 billion, reflecting continued strength in core businesses.
Hologic, Inc. (NASDAQ: HOLX) will release its fourth quarter fiscal 2022 financial results on October 31, after market close. The management will host a conference call at 4:30 p.m. Eastern Time on the same day. Interested parties can join the call by dialing designated numbers or via a provided link. A replay will be available for listening until November 30, 2022. Hologic focuses on improving women's health through innovative medical technology and treatment solutions.
Hologic Inc. rang the Nasdaq opening bell to commence Breast Cancer Awareness Month, marking the 16th occasion for this event. The company emphasized the importance of regular screenings, highlighting that over 2 billion women worldwide did not undergo cancer screenings in the past year. Tennis legend Martina Navratilova, a breast cancer survivor, joined Hologic's leadership to stress preventive care. The ongoing partnership with the Women’s Tennis Association aims to promote women's health awareness during tournaments and special events.
The second annual Hologic Global Women’s Health Index reveals that over 1.5 billion women lack necessary health screenings, including cancer and diabetes. The report highlights significant barriers to women's health, including food insecurity, safety threats, and educational gaps. The average global health score was just 53 out of 100, with Taiwan leading at 70 and Afghanistan at the lowest with 22. The Index stresses the need for better preventive care, addressing emotional health, and enhancing socioeconomic equity to improve women’s wellbeing.
Hologic, Inc. (NASDAQ: HOLX) announced its participation in two upcoming investor conferences. The first is Wells Fargo’s Healthcare Conference on September 7 at 9:45 a.m. ET, followed by Morgan Stanley’s 20th Annual Global Healthcare Conference on September 13 at 12:20 p.m. ET. Both presentations will be webcast live and available for 30 days post-event through Hologic's investor website. Hologic is dedicated to enhancing women’s health through early detection and treatment.
Hologic, Inc. (NASDAQ: HOLX), a leader in women’s health, announces its sponsorship of Mary J. Blige’s “Good Morning Gorgeous” tour from September 17 to October 29, 2022. The initiative aims to promote preventive care and Well Woman Exams. The partnership includes a sweepstakes for fans to win concert tickets and a public service announcement featuring Blige. Hologic emphasizes the importance of screenings, particularly for underserved communities, showcasing its commitment to women's health.
Hologic, Inc. (NASDAQ: HOLX) received a favorable ruling from the U.S. Court of Appeals for the Federal Circuit, which upheld a 2018 district court decision blocking Minerva from disputing the validity of patents assigned to Hologic. This ruling, relating to a lawsuit filed in 2015 over alleged patent infringement by Minerva’s endometrial ablation system, requires Minerva to pay Hologic over $7 million in damages. Hologic's acquisition of Novacept's patents in 2004 has been confirmed, fostering confidence for companies acquiring innovative technologies in the medical field.
Active Motif has licensed its foundational patents in transposition for CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). This licensing agreement aims to enhance the understanding of biological processes through improved access to patented technologies, including US9938524 and others. The Cut&Tag-IT technology will aid mechanistic, translational, and clinical research. Active Motif focuses on developing tools for nuclear function analysis, serving a global customer base in scientific and pharmaceutical fields.
Hologic, Inc. reported third-quarter revenue of $1.003 billion, with GAAP diluted EPS of $0.90 and non-GAAP diluted EPS of $0.95, exceeding expectations. Global organic molecular diagnostics revenue grew over 20% in constant currency, while overall revenue declined 14.2% year-over-year, mainly due to lower COVID-19 assay sales and semiconductor supply chain issues. The company has raised its full-year revenue and EPS guidance, reflecting confidence in its diagnostics and surgical business.
Hologic, Inc. (NASDAQ: HOLX) is set to showcase its innovative breast and skeletal health solutions at the European Congress of Radiology in Vienna from July 13-17. The company aims to address challenges in early detection caused by pandemic delays. Attendees can explore Hologic's 3D Mammography™ technology and participate in scientific talks at the Scientific Innovation Hub. Highlights from the inaugural Hologic Global Women’s Health Index will also be shared, focusing on women's health perspectives. This event underscores Hologic's commitment to improving women's health.